NFE2L2 and tauopathy: While compounds derived from licochalcone A have been shown to reduce neuroinflammation25 and to attenuate beta-amyloid aggregation26, a central player of AD, evidence about the protectiveness of other Nrf2-pathway activators in tauopathies, such as Ki 696 or HPP-D, is very limited as almost no studies are currently available.